RPG Life Sciences Limited (RPGLIFE.NS)
INR 2267.75
(3.54%)
INR 2267.75
(3.54%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.01 Billion INR | 6.26% |
| 2022 | 950.5 Million INR | 14.53% |
| 2021 | 829.9 Million INR | 42.28% |
| 2020 | 583.3 Million INR | 25.14% |
| 2019 | 466.1 Million INR | 13.57% |
| 2018 | 410.4 Million INR | -23.56% |
| 2017 | 536.9 Million INR | 17.28% |
| 2016 | 457.8 Million INR | 17.32% |
| 2015 | 390.2 Million INR | 13.17% |
| 2014 | 344.8 Million INR | -8.71% |
| 2013 | 377.7 Million INR | 28.6% |
| 2012 | 293.7 Million INR | 1.31% |
| 2011 | 289.9 Million INR | 10.17% |
| 2010 | 263.14 Million INR | 76.56% |
| 2009 | 149.04 Million INR | 5.63% |
| 2008 | 141.09 Million INR | -7.74% |
| 2007 | 152.92 Million INR | -20.64% |
| 2006 | 192.7 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 1.01 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 1.01 Billion INR | 6.26% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 1 Billion INR | 0.0% |
| 2022 FY | 950.5 Million INR | 14.53% |
| 2022 Q4 | 950.5 Million INR | 0.0% |
| 2022 Q2 | 848 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 672.2 Million INR | 0.0% |
| 2021 Q4 | 829.9 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 829.9 Million INR | 42.28% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 606.6 Million INR | 0.0% |
| 2020 Q4 | 583.3 Million INR | 0.0% |
| 2020 FY | 583.3 Million INR | 25.14% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 416.2 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 466.1 Million INR | 13.57% |
| 2019 Q4 | 466.1 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 410.4 Million INR | -23.56% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 468.6 Million INR | 0.0% |
| 2018 Q4 | 410.4 Million INR | 0.0% |
| 2017 Q4 | 536.9 Million INR | 0.0% |
| 2017 FY | 536.9 Million INR | 17.28% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 441.1 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 457.8 Million INR | 17.32% |
| 2016 Q4 | 457.8 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 470.2 Million INR | 0.0% |
| 2015 FY | 390.2 Million INR | 13.17% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 387.1 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 390.2 Million INR | 0.0% |
| 2014 FY | 344.8 Million INR | -8.71% |
| 2014 Q4 | 344.8 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 382 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q4 | 377.7 Million INR | 0.0% |
| 2013 FY | 377.7 Million INR | 28.6% |
| 2013 Q2 | 397.9 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q4 | 293.7 Million INR | 0.0% |
| 2012 Q2 | 696.6 Million INR | 0.0% |
| 2012 FY | 293.7 Million INR | 1.31% |
| 2011 FY | 289.9 Million INR | 10.17% |
| 2010 FY | 263.14 Million INR | 76.56% |
| 2009 FY | 149.04 Million INR | 5.63% |
| 2008 FY | 141.09 Million INR | -7.74% |
| 2007 FY | 152.92 Million INR | -20.64% |
| 2006 FY | 192.7 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Sigachi Industries Limited | 707.2 Million INR | -42.815% |
| Ind-Swift Limited | 640.91 Million INR | -57.587% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 29.88% |
| Sakar Healthcare Limited | 277.32 Million INR | -264.196% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 98.97% |
| Innova Captab Limited | 1.44 Billion INR | 29.869% |
| Divi's Laboratories Limited | 31.84 Billion INR | 96.828% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 55.679% |
| Morepen Laboratories Limited | 2.48 Billion INR | 59.372% |
| Mankind Pharma Limited | 15.53 Billion INR | 93.498% |
| Sequent Scientific Limited | 3.46 Billion INR | 70.829% |
| Wanbury Limited | 360.23 Million INR | -180.375% |
| Laurus Labs Limited | 18.45 Billion INR | 94.527% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 85.758% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 84.848% |
| Alembic Limited | 113.4 Million INR | -790.653% |
| Hikal Limited | 3.03 Billion INR | 66.746% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 93.855% |
| Neuland Laboratories Limited | 3.5 Billion INR | 71.178% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 79.901% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 95.981% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 76.226% |
| Themis Medicare Limited | 705.74 Million INR | -43.112% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 97.066% |
| Lupin Limited | 49.53 Billion INR | 97.961% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -249.424% |
| Wockhardt Limited | 6.4 Billion INR | 84.219% |
| Vaishali Pharma Limited | 3.79 Million INR | -26499.947% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 84.289% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -573.468% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 92.168% |
| FDC Limited | 3.88 Billion INR | 74.029% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 98.411% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -2432.598% |
| Eris Lifesciences Limited | 1.89 Billion INR | 46.57% |
| Venus Remedies Limited | 1.21 Billion INR | 17.002% |
| ZIM Laboratories Limited | 812.62 Million INR | -24.288% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 14.73% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -2318.003% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | 72.179% |
| Shilpa Medicare Limited | 3.44 Billion INR | 70.719% |
| Albert David Limited | 436.12 Million INR | -131.587% |
| Ajanta Pharma Limited | 8.28 Billion INR | 87.807% |
| Hester Biosciences Limited | 755.81 Million INR | -33.631% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 56.314% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 71.921% |
| Gufic Biosciences Limited | 2 Billion INR | 49.621% |
| Windlas Biotech Limited | 621.89 Million INR | -62.408% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 7.433% |
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | -191.27% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 18.311% |
| Granules India Limited | 13 Billion INR | 92.234% |
| Aarti Drugs Limited | 4.85 Billion INR | 79.213% |
| Bal Pharma Limited | 878.11 Million INR | -15.019% |
| Alkem Laboratories Limited | 26.61 Billion INR | 96.205% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 98.977% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | -30.883% |
| Medicamen Biotech Limited | 593.75 Million INR | -70.105% |
| Unichem Laboratories Limited | 7.04 Billion INR | 85.667% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | -240.735% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -3861.25% |
| Valiant Laboratories Limited | 100.15 Million INR | -908.447% |
| Orchid Pharma Limited | 2.64 Billion INR | 61.775% |
| Medico Remedies Limited | 163.37 Million INR | -518.221% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -865.796% |
| Ipca Laboratories Limited | 24.71 Billion INR | 95.913% |
| Brooks Laboratories Limited | 96.1 Million INR | -950.901% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -379.093% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 95.568% |
| NATCO Pharma Limited | 7 Billion INR | 85.582% |
| Suven Life Sciences Limited | 7.08 Million INR | -14155.469% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -930.991% |
| Strides Pharma Science Limited | 11.26 Billion INR | 91.032% |
| Indoco Remedies Limited | 3.53 Billion INR | 71.393% |
| Alpa Laboratories Limited | 136.65 Million INR | -639.098% |
| Lasa Supergenerics Limited | 190.43 Million INR | -430.367% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -6728.015% |